Feature

Never too late to operate? Surgery near end of life is common, costly


 


That clarity came only during a subsequent visit to a different hospital, when a surprised ER doctor saw a defibrillator protruding from the DNR patient’s thin chest. To Stanich’s horror, the ER doctor explained that the device would not allow her to slip away painlessly and that the jolt would be “so strong that it will knock her across the room,” said Giaquinto, who accompanied her mother on both hospital trips.

Surgery like this has become all too common among those near the end of life, experts say. Nearly one in three Medicare patients undergo an operation in the year before they die, even though the evidence shows that many are more likely to be harmed than to benefit from it.

The practice is driven by financial incentives that reward doctors for doing procedures, as well as a medical culture in which patients and doctors are reluctant to talk about how surgical interventions should be prescribed more judiciously, said Rita Redberg, M.D., a cardiologist who treated Stanich when she sought care at the second hospital.

“We have a culture that believes in very aggressive care,” said Dr. Redberg, who at the University of California–San Francisco specializes in heart disease in women. “We are often not considering the chance of benefit and chance of harm, and how that changes when you get older. We also fail to have conversations about what patients value most.”

Pages

Recommended Reading

Opioids a focus as HHS Secretary Azar defends White House budget proposal
MDedge Hematology and Oncology
Allscripts’ charges for sending, refilling prescriptions
MDedge Hematology and Oncology
Trump administration proposes rule to loosen curbs on short-term health plans
MDedge Hematology and Oncology
Cyberliability insurance: Should you purchase a policy?
MDedge Hematology and Oncology
Hospital chemo carries higher price tag than the office
MDedge Hematology and Oncology
Will Indiana Medicaid work requirements pass legal muster?
MDedge Hematology and Oncology
Evaluations of Medicaid experiments by states, CMS are weak, GAO says
MDedge Hematology and Oncology
Supreme Court declines to hear DACA case
MDedge Hematology and Oncology
Expert argues for improving MACRA, not scrapping it
MDedge Hematology and Oncology
Americans support the right to affordable health care
MDedge Hematology and Oncology